<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01300949</url>
  </required_header>
  <id_info>
    <org_study_id>10-998</org_study_id>
    <nct_id>NCT01300949</nct_id>
  </id_info>
  <brief_title>Spaeth/Richman Contrast Sensitivity Test</brief_title>
  <acronym>SPARCS</acronym>
  <official_title>Validation and Reproducibility of Spaeth/Richman Contrast Sensitivity Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Spaeth-Richman Contrast Sensitivity (SPARCS) test is a new method of assessing contrast
      sensitivity. The test, another way to measure vision, is performed on any standard computer
      with internet access. Patients will be tested with SPARCS and with the standard Pelli-Robson
      contrast test.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Contrast Sensitivity is another way to test vision. It uses black on a white background and
      minimally decreases the black (grey) until it blends with the white. The least amount of
      contrast (faint grey) seen translates into amount of vision. This new method of determining
      contrast sensitivity uses black and white vertical bars and does not require recognizing
      letters in the alphabet. It tests various areas of the visual field and central vision. The
      test takes approximately 3 minutes per eye.

      Pelli-Robson is a commonly used contrast sensitivity test that uses black letters on a white
      background. The letter size stays the same, only the amount of black changes, becoming
      greyer, making letters hard to see. The test takes approximately 1 minute per eye.

      Hypothesis: A method of determining contrast sensitivity that does not require letter
      recognition (as does the Pelli-Robson test) eliminates the barriers of literacy and pattern
      recognition, to permit a more valid determination of contrast sensitivity.

      Patients will perform SPARCS and Pelli-Robson twice; once each with two separate observers
      for reproducibility and intra-observer reliability. The order of testing will be randomized
      to SPARCS, Pelli, Pelli, SPARCS or Pelli, SPARCS, SPARCS, Pelli.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2010</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Contrast sensitivity, another means of testing vision, will be measured two ways for each participant. One method uses the Pelli-Robson Contrast Sensitivity Chart which is mounted on the wall, the other method uses a new computerized program called Spaeth/Richman Contrast Sensitivity Test also known as SPARCS.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contrast Sensitivity, Another Means of Testing Vision</measure>
    <time_frame>duration of 1 eye exam, approximately 1 hour</time_frame>
    <description>Contrast Sensitivity, a vision measurement, is performed with the Spaeth Richmond Contrast Sensitivity (SPARCS) test. This is a computerized measurement of vision in the central and peripheral fields using black and white stripes. Black stripes decrease in contrast becoming fainter and harder to see until they blend with the white background. Measurements are assessed in five areas of the visual field . Test results are reported for each area ranging from 0 to 20 (0 means can't see stripes; 20 means sees all stripes). Results from all 5 areas are added making the total SPARCS score range 0 - 100 where 0 means poor vision and 100 means best vision. The test takes an average of 3 minutes per eye. The eye not being tested is covered with a patch.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">314</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Glaucoma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>154 glaucoma, ocular hypertension and glaucoma suspect patients will have contrast sensitivity measured by Spaeth/Richman Contrast Sensitivity Test (SPARCS) and Pelli-Robson Contrast Sensitivity Chart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>125 patients with no eye diseases will have contrast sensitivity measured by Spaeth/Richman Contrast Sensitivity Test (SPARCS) and Pelli-Robson Contrast Sensitivity Chart. This included patients with refractive errors (needing glasses) and nuclear sclerosis (cataract).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age-Related Macular Degeneration (ARMD)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>35 retina patients with age-related macular degeneration (ARMD) will have contrast sensitivity measured by Spaeth/Richman Contrast Sensitivity Test (SPARCS) and Pelli-Robson Contrast Sensitivity Chart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Spaeth/Richman Contrast Sensitivity Test</intervention_name>
    <description>internet based computerized contrast sensitivity test measuring central and peripheral vision using black and white stripes that decrease in contrast by fading to a white background.</description>
    <arm_group_label>Age-Related Macular Degeneration (ARMD)</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Glaucoma</arm_group_label>
    <other_name>SPARCS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Pelli-Robson Contrast Sensitivity Chart</intervention_name>
    <description>wall chart contrast sensitivity test measuring central vision using black letters that decrease in contrast by fading to a white background.</description>
    <arm_group_label>Age-Related Macular Degeneration (ARMD)</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Glaucoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 yrs of age and older

          -  able to provide fully informed consent

             70 controls (patients with no ocular disease affecting visual acuity or visual
             function), 10 from each decade of life: 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80+.

             105 patients with ocular hypertension or any type of glaucoma (15 subjects per age
             decade). Glaucoma patients will not have macular degeneration or visual acuity
             affected by any function other than glaucoma.

             40 patients with macular degeneration: 10 with visual acuity 20/40 or better, 10 with
             visual acuity between 20/40 and 20/60, 10between 20/100 and 20/400, and 10 with 20/400
             or worse.

             40 patients with cataracts: 10 with lens opacity 1+nuclear sclerosis, 10 with 2 +
             nuclear sclerosis, 10 with 3 + nuclear sclerosis, 10 with 4 + nuclear sclerosis.

             60 patients with refractive error: 10 with myopia -5 diopters or greater, 10 with
             myopia between -5 and -2.5, 10 with myopia between -2.5 and -0.5, 10 with myopia
             between -0.5 and 0.5, 10 with myopia between 0.5 and 2.5, and 10 with myopia &gt; 2.5.

        Exclusion Criteria:

          -  any other diseases affecting visual acuity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George L Spaeth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glaucoma Service, Wills Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wills Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Richman J, Zangalli C, Lu L, Wizov SS, Spaeth E, Spaeth GL. The Spaeth/Richman contrast sensitivity test (SPARCS): design, reproducibility and ability to identify patients with glaucoma. Br J Ophthalmol. 2015 Jan;99(1):16-20. doi: 10.1136/bjophthalmol-2014-305223. Epub 2014 Jul 22.</citation>
    <PMID>25053760</PMID>
  </results_reference>
  <results_reference>
    <citation>Faria BM, Duman F, Zheng CX, Waisbourd M, Gupta L, Ali M, Zangalli C, Lu L, Wizov SS, Spaeth E, Richman J, Spaeth GL. EVALUATING CONTRAST SENSITIVITY IN AGE-RELATED MACULAR DEGENERATION USING A NOVEL COMPUTER-BASED TEST, THE SPAETH/RICHMAN CONTRAST SENSITIVITY TEST. Retina. 2015 Jul;35(7):1465-73. doi: 10.1097/IAE.0000000000000474.</citation>
    <PMID>25658175</PMID>
  </results_reference>
  <results_reference>
    <citation>Sun Y, Erdem E, Lyu A, Zangalli C, Wizov SS, Lo D, Spaeth EE, Richman J, Spaeth GL. The SPARCS: a novel assessment of contrast sensitivity and its reliability in patients with corrected refractive error. Br J Ophthalmol. 2016 Oct;100(10):1421-6. doi: 10.1136/bjophthalmol-2015-307378. Epub 2016 Jan 12.</citation>
    <PMID>26758536</PMID>
  </results_reference>
  <results_reference>
    <citation>Gupta L, Cvintal V, Delvadia R, Sun Y, Erdem E, Zangalli C, Lu L, Wizov SS, Richman J, Spaeth E, Spaeth GL. SPARCS and Pelli-Robson contrast sensitivity testing in normal controls and patients with cataract. Eye (Lond). 2017 May;31(5):753-761. doi: 10.1038/eye.2016.319. Epub 2017 Jan 20.</citation>
    <PMID>28106888</PMID>
  </results_reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>February 22, 2011</study_first_submitted>
  <study_first_submitted_qc>February 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2011</study_first_posted>
  <results_first_submitted>November 22, 2017</results_first_submitted>
  <results_first_submitted_qc>October 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 8, 2018</results_first_posted>
  <last_update_submitted>November 16, 2018</last_update_submitted>
  <last_update_submitted_qc>November 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>George L. Spaeth MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Contrast Sensitivity</keyword>
  <keyword>Pelli-Robson Test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Multiple manuscripts have been published.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Glaucoma</title>
          <description>154 glaucoma, ocular hypertension and glaucoma suspect patients</description>
        </group>
        <group group_id="P2">
          <title>Controls</title>
          <description>125 patients with no eye diseases. This included patients with refractive errors (needing glasses) and nuclear sclerosis (cataract).</description>
        </group>
        <group group_id="P3">
          <title>Age-Related Macular Degeneration (ARMD)</title>
          <description>35 retina patients with age-related macular degeneration (ARMD)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
                <participants group_id="P2" count="125"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
                <participants group_id="P2" count="125"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Glaucoma</title>
          <description>154 glaucoma, ocular hypertension and glaucoma suspect patients</description>
        </group>
        <group group_id="B2">
          <title>Controls</title>
          <description>125 patients with no eye diseases. This included patients with refractive errors (needing glasses) and nuclear sclerosis (cataract).</description>
        </group>
        <group group_id="B3">
          <title>Age-Related Macular Degeneration (ARMD)</title>
          <description>35 retina patients with age-related macular degeneration (ARMD)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="154"/>
            <count group_id="B2" value="125"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="314"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="19" upper_limit="98"/>
                    <measurement group_id="B2" value="49" lower_limit="20" upper_limit="83"/>
                    <measurement group_id="B3" value="81" lower_limit="74" upper_limit="88"/>
                    <measurement group_id="B4" value="62" lower_limit="19" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="162"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Contrast Sensitivity, Another Means of Testing Vision</title>
        <description>Contrast Sensitivity, a vision measurement, is performed with the Spaeth Richmond Contrast Sensitivity (SPARCS) test. This is a computerized measurement of vision in the central and peripheral fields using black and white stripes. Black stripes decrease in contrast becoming fainter and harder to see until they blend with the white background. Measurements are assessed in five areas of the visual field . Test results are reported for each area ranging from 0 to 20 (0 means can't see stripes; 20 means sees all stripes). Results from all 5 areas are added making the total SPARCS score range 0 - 100 where 0 means poor vision and 100 means best vision. The test takes an average of 3 minutes per eye. The eye not being tested is covered with a patch.</description>
        <time_frame>duration of 1 eye exam, approximately 1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glaucoma</title>
            <description>154 glaucoma, ocular hypertension and glaucoma suspect patients
Spaeth/Richman Contrast Sensitivity Test: internet based computerized contrast sensitivity test measuring central and peripheral vision using black and white stripes
Pelli-Robson Contrast Sensitivity Chart: chart measuring central vision with black letters fading to white on a white background</description>
          </group>
          <group group_id="O2">
            <title>Controls</title>
            <description>125 patients with no eye diseases. This included patients with refractive errors (needing glasses) and nuclear sclerosis (cataract).
Spaeth/Richman Contrast Sensitivity Test: internet based computerized contrast sensitivity test measuring central and peripheral vision using black and white stripes
Pelli-Robson Contrast Sensitivity Chart: chart measuring central vision with black letters fading to white on a white background</description>
          </group>
          <group group_id="O3">
            <title>Age-Related Macular Degeneration (ARMD)</title>
            <description>35 retina patients with age-related macular degeneration (ARMD)
Spaeth/Richman Contrast Sensitivity Test: internet based computerized contrast sensitivity test measuring central and peripheral vision using black and white stripes
Pelli-Robson Contrast Sensitivity Chart: chart measuring central vision with black letters fading to white on a white background</description>
          </group>
        </group_list>
        <measure>
          <title>Contrast Sensitivity, Another Means of Testing Vision</title>
          <description>Contrast Sensitivity, a vision measurement, is performed with the Spaeth Richmond Contrast Sensitivity (SPARCS) test. This is a computerized measurement of vision in the central and peripheral fields using black and white stripes. Black stripes decrease in contrast becoming fainter and harder to see until they blend with the white background. Measurements are assessed in five areas of the visual field . Test results are reported for each area ranging from 0 to 20 (0 means can't see stripes; 20 means sees all stripes). Results from all 5 areas are added making the total SPARCS score range 0 - 100 where 0 means poor vision and 100 means best vision. The test takes an average of 3 minutes per eye. The eye not being tested is covered with a patch.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.4" spread="15.3"/>
                    <measurement group_id="O2" value="74.4" spread="5.0"/>
                    <measurement group_id="O3" value="53.9" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>duration of 1 eye exam, approximately 1 hour</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Glaucoma</title>
          <description>154 glaucoma, ocular hypertension and glaucoma suspect patients</description>
        </group>
        <group group_id="E2">
          <title>Controls</title>
          <description>125 patients with no eye diseases. This included patients with refractive errors (needing glasses) and nuclear sclerosis (cataract).</description>
        </group>
        <group group_id="E3">
          <title>Age-Related Macular Degeneration (ARMD)</title>
          <description>35 retina patients with age-related macular degeneration (ARMD)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>George L. Spaeth, MD</name_or_title>
      <organization>Wills Eye Hospital</organization>
      <phone>215-928-3123</phone>
      <email>gspaeth@willseye.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

